Most recently, she has led the planning and execution of a program for a new
gene therapy product candidate, from ideation through proof - of - concept study, and mapping out the development plan.
AGTC plans to use the net proceeds of the offering to fund preclinical investigation and Phase 1/2 trials of potential
product candidates for treatment of wet AMD; to expand its manufacturing capabilities and create a pilot manufacturing group; to in - license, acquire or invest in complementary
gene therapy, technologies,
products or assets; and for working capital and other general corporate purposes.